

SEQUENCE LISTING

<110> Niles, Andrew L
Haak-Frendscho, Mary
Harris, Jennifer L
Craik, Charles S

<120> Tryptase Substrates and Assay For Tryptase Activity Using Same

<130> 34506.xxx

<140> Filed Herewith

<141> 2001-09-19

<150> 60/244,013

<151> 2000-10-27

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 is Arg (R) or Lysine (K)

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 is any amino acid

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 is Arg (R) or Lys (K)

<400> 1

Pro Xaa Xaa Xaa

1

<210> 2

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 2

Pro Arg Asn Lys

1

<210> 3

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 3

Pro Lys Asn Lys

1

<210> 4

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 4

Pro Arg Asn Arg

1

<210> 5

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 5

Pro Lys Asn Arg

1

<210> 6

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 6

Pro Ala Asn Lys

1

<210> 7

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 7

Pro Arg Thr Lys

1

<210> 8

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 8

Pro Arg Phe Lys

1

<210> 9

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 9

Thr Arg Leu Arg

1

<210> 10

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 10

Ser Lys Gly Arg

1

<210> 11

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 11

Pro Asn Asp Lys

1

<210> 12

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to contain an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to contain a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 12

Pro Arg Asn Lys

1

<210> 13

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<400> 13

Pro Arg Asn Lys

1

<210> 14

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal chloromethyl ketone group

<400> 14

Pro Arg Asn Lys

1

<210> 15

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 15

Pro Arg Asn Lys

1

<210> 16

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 16

Pro Arg Thr Lys

1

<210> 17
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide
 <220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> P at position 1 is modified to include an N-terminal acetyl group

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 17

Pro Arg Asn Arg

1

<210> 18
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLTATION

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> N-METHYLATION

<400> 18

Pro Arg Asn Lys

1

<210> 19
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<400> 19

Pro Arg Phe Lys

1

<210> 20
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<400> 20

Ile Arg Ser Lys

1

<210> 21
 <211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 21

Ser Lys Gly Arg

1

<210> 22

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 22

Phe Arg Thr Lys

1

<210> 23

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 23

Ile Lys Thr Lys

1